Premium
A prospective study of detorubicin in malignant mesothelioma
Author(s) -
Colbert Nicolas,
Vannetzel JeanMichel,
Izrael Victor,
Schlienger Michel,
Milleron Bernard,
Blanchon Francois,
Herman Dominique,
Akoun Georges,
Roland Jean,
Chatelet Francois,
Laugier Alain
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19851101)56:9<2170::aid-cncr2820560905>3.0.co;2-l
Subject(s) - medicine , mesothelioma , prospective cohort study , chemotherapy , chest pain , surgery , heart failure , gastroenterology , pathology
Between January 1981 and December 1983, a prospective therapeutic trial of detorubicin (14‐diethoxyacetoxy‐daunorubicin [DTR]) was conducted in 40 patients with histologically proven malignant mesothelioma (MM). DTR was given intravenously at 40 mg/m 2 on days 1, 2, and 3 for five 21‐day cycles, then 40 mg/m 2 once every 21 days. Thirty‐five patients (32 with pleural MM, 3 with peritoneal MM) were eligible. The overall median survival from onset of chemotherapy was 17 months. Complete relief from chest pain was observed in 8 of 15 cases (53%). Of 21 patients with measurable disease, there were 2 complete responses (10%) and 7 partial responses (33%). Median duration of response was 30 weeks. Congestive cardiac failure developed in two patients after 1100 and 1600 mg/m 2 of DTR, respectively. Hematologic toxicity was moderate. This study demonstrates that DTR is effective against MM.